

REVIEW

The effect of adolescent inhalant abuse on energy balance and growth

Rose Crossin^{1,2,3} | Ashleigh Qama^{1,4} | Zane B. Andrews⁵ |
Andrew J. Lawrence^{1,6} | Jhodie R. Duncan¹

¹Florey Institute of Neuroscience and Mental Health, Parkville, VIC

²Turning Point, Eastern Health, Richmond, VIC

³Eastern Health Clinical School, Monash University, Box Hill, VIC

⁴WHO Collaborating Centre for Viral Hepatitis, Peter Doherty Institute for Infection and Immunity, Melbourne, VIC

⁵Monash Biomedicine Discovery Institute, Monash University, Clayton, VIC

⁶Florey Department of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC

Correspondence

Rose Crossin, 30 Royal Parade, Parkville, VIC.
Email: rose.crossin@florey.edu.au

Funding information

National Health and Medical Research Council, Grant/Award Number: 1116930 and APP 1154974

Abstract

The abuse of volatile solvents such as toluene is a significant public health concern, predominantly affecting adolescents. To date, inhalant abuse research has primarily focused on the central nervous system; however, inhalants also exert effects on other organ systems and processes, including metabolic function and energy balance. Adolescent inhalant abuse is characterized by a negative energy balance phenotype, with the peak period of abuse overlapping with the adolescent growth spurt. There are multiple components within the central and peripheral regulation of energy balance that may be affected by adolescent inhalant abuse, such as impaired metabolic signaling, decreased food intake, altered dietary preferences, disrupted glucose tolerance and insulin release, reduced adiposity and skeletal density, and adrenal hypertrophy. These effects may persist into abstinence and adulthood, and the long-term consequences of inhalant-induced metabolic dysfunction are currently unknown. The signs and symptoms resulting from chronic adolescent inhalant abuse may result in a propensity for the development of adult-onset metabolic disorders such as type 2 diabetes, however, further research investigating the long-term effects of inhalant abuse upon energy balance and metabolism are needed. This review addresses several aspects of the short- and long-term effects of inhalant abuse relating to energy and metabolic processes, including energy balance, intake and expenditure; dietary preferences and glycemic control; and the dysfunction of metabolic homeostasis through altered adipose tissue, bone, and hypothalamic-pituitary-adrenal axis function.

KEYWORDS

addiction, adolescence, endocrine, energy balance, glycemic control, growth, inhalant abuse, metabolism, substance abuse, toluene, volatile solvent abuse

Abbreviations: ACTH, adrenocorticotrophic hormone; CNS, central nervous system; CRH, corticotrophic-releasing hormone; GABA, gamma-Aminobutyric acid; GTT, glucose tolerance test; HPA, hypothalamic-pituitary-adrenal; NMDA, N-methyl-D-aspartate; NPY, neuropeptide Y; PYY, peptide YY; ppm, parts per million.

Rose Crossin and Ashleigh Qama are joint first authors.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2019 The Authors. *Pharmacology Research & Perspectives* published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.

1 | AN OVERVIEW OF INHALANT ABUSE

Inhalant abuse is a form of substance abuse and involves the intentional inhalation of vapors from household or industrial products, in order to create a feeling of euphoria and an altered mental state.¹ Products that are commonly abused as inhalants include petrol, spray paint, thinners, aerosols, and glue. These products are cheap, legal to purchase, and readily accessible, which is thought to add to their attractiveness as substances of abuse.² While inhaled products are not technically considered “drugs,” they share the reinforcing nature of many drugs of abuse due to the presence of toluene, which is common to all these products. Petrol is approximately 7% toluene, whereas some spray paint and thinners can be up to 35% toluene, with highly variable percentages in glues and adhesives,³ though inhalant users report preferring pure toluene when it is available.⁴ Toluene is a volatile solvent; a colorless, water-insoluble aromatic hydrocarbon, and is considered to underlie the addictive drive to continue abusing inhalants, therefore, toluene is commonly used as an experimental preclinical model for inhalant abuse. Thus, in this review, “inhalants” and “toluene” are used interchangeably, depending on whether reference is being made to clinical or preclinical studies.

Inhalant abuse is commonly known as “chroming,” “huffing,” or “bagging” as typical self-administration involves inhaling concentrated vapors from spray cans, off solvent-soaked cloth, or directly from a bag, respectively. When administered in these ways, the concentration of inhaled toluene is estimated to range from 3000 to 15 000 parts per million (ppm) (equivalent to 0.03-0.16 mol/L).⁵ While the abuse of inhalants generally occurs for a short duration, ranging from minutes to 1 hour, for the majority of individuals this behavior is repeated over time and extends for periods greater than 1 year, such that the exposure becomes chronic but intermittent in nature.⁶ It is also important to note that, as well as intentional inhalation, exposure to inhaled toluene can also occur in industrial settings (eg, in factories where toluene is used as a solvent). Both the patterns of use and concentrations of inhaled toluene differentiate inhalant abuse from occupational exposure, with occupational exposure characterized by sustained contact to concentrations of toluene less than 200 ppm.^{7,8} While this review focuses on inhalant abuse, it is acknowledged that some of the data pertaining to the toxicology of toluene has been determined using occupational exposure studies and these should be interpreted with caution relative to effects in the abuse setting; these studies are highlighted when discussed.

2 | ADOLESCENT INHALANT ABUSE

Inhalant abuse is predominantly an issue in young adolescent populations (Figure 1), with prevalence rates approximately equal between males and females.⁹ Inhalants are one of the first and most common substances abused by the 12-13 age group in Australia, with 14% of 12-year-olds having misused inhalants in the previous year, and of those, approximately 20% have misused inhalants 10




FIGURE 1 Past year inhalant use in Australian secondary school students, by gender, based on data sourced from the 2014 Australian Secondary School Drug Survey. The data highlight that, amongst all adolescents, the predominant age group misusing inhalants is young adolescents, with use decreasing as age increases. Figure adapted from data provided in⁹

or more times in that year.^{9,10} This pattern of early adolescent use is consistent globally.¹¹ A recent survey by the Australian government found that, overall, inhalant abuse in Australia is increasing, with rates of recent inhalant use doubling more between 2007 and 2016 compared to a 4% reduction in recent alcohol and cigarette use over the same period.¹⁰ Similarly, the most recent United States Monitoring the Future Survey also reported a significant increase in recent use in Grade 8 students (aged 13-14) along with a decline in the perceived risk of inhalant misuse.¹²

3 | THE EFFECTS OF INHALANT ABUSE ON ENERGY BALANCE

The effects of inhalants on the central nervous system (CNS), including cognition, have been relatively well studied,¹³⁻¹⁵ and it is thought that inhibited *N*-methyl-D-aspartate (NMDA) receptor signaling and region-specific changes to glutamatergic and gamma-Aminobutyric acid (GABA)-ergic signaling underpin these effects.^{16,17} However, inhalants can also have a wide range of peripheral effects throughout the body, including on the renal, cardiovascular, and pulmonary systems.¹⁸ Indeed, one of the most profound, but underexplored, consequences of inhalant abuse is its effect on energy balance. In humans, adolescent inhalant abuse is associated with weight loss,^{19,20} and emaciation²¹; findings which are supported by meta-analysis.²² This meta-analysis found a significant dose-response relationship to toluene-induced weight impairments, with the lowest concentration band (0-500 ppm) having no significant impact on body weight, suggesting that occupational level exposure does not impact body weight in the same way as inhalant abuse.²² Furthermore, one cohort study found that the weight suppressing effects of inhalant abuse was not mediated by other substance use, suggesting that inhalants are a strong mediator of this effect even with other drug-drug interactions.¹⁹ Indeed, this effect on body weight is listed as a warning sign of inhalant abuse.²³ Inhalant abuse in both males and females has been associated with disordered eating, including

FIGURE 2 The energy balance equation. Figure by R Crossin, first cited in¹⁰⁸



fasting, purging, and other behaviors associated with attempts to lose weight,²⁴ suggesting that inhalants may be used as a means of suppressing appetite and thus body weight.^{24,25} These findings are consistent with preclinical studies using rats, with adolescent and adult toluene exposure associated with reduced food intake, decreased weight gain, and reduced fat deposition.²⁶⁻³⁰

In addition to effects on food intake and body weight, exposure to toluene is associated with impaired linear growth.²² A clinical study of Indigenous males found that those with a history of chronic inhalant abuse in adolescence were, on average, 7 cm shorter than noninhalant users from the same communities¹⁹; this height impairment persisted into sustained abstinence.³¹ In weanling and adolescent rats, chronic toluene exposure at concentrations analogous to inhalant abuse impairs growth, with a significant reduction in rump width and body length.^{26,32}

The impact of inhalants on food intake, body weight, and growth is of importance given the association between inhalant abuse and adolescence. During adolescence, critical maturational processes occur, including the adolescent growth spurt,³³ where skeletal structures grow and mature.³⁴ Indeed, in humans, over half of the peak bone mass is attained during the adolescent growth spurt.^{34,35} However, the adolescent growth spurt can be disrupted by factors such as malnutrition³⁶ or exposure to estrogenic chemicals.³⁷ Growth impairments can potentially recover if the harmful factor is removed, but if exposure occurs during adolescence usually only partial recovery is possible.³⁸ Thus, any disruption to growth during adolescence has the potential to cause long-term effects on growth patterns.³⁹ Given that the highest rates of inhalant abuse are occurring during this critical period, studying the energy balance impacts of inhalant abuse specifically in adolescents, including the long-term effects even if exposure ceases, is essential. This review will summarize the current understanding of the effects of inhalants on growth and energy balance.

4 | AN OVERVIEW OF ENERGY BALANCE

Food intake, body weight, and growth are intrinsically linked and can be represented via the energy balance equation (Figure 2). Energy intake is primarily driven by food intake and moderated by absorption and excretion. Energy expenditure includes basal metabolic rate, physical activity, and thermogenesis (subdivided into cold-induced thermogenesis and the thermic effect of food). Body weight will remain stable when there is a balance between energy intake, storage, and expenditure; a process known as energy homeostasis.⁴⁰

The maintenance of body weight is buffered, that is, a decrease in energy intake results in decreased expenditure and vice versa, therefore, any change in body weight occurs by overwhelming the buffering potential of homeostatic systems.⁴¹

Negative energy balance occurs when energy intake is less than the energy expenditure, and this shortfall is made up by a release of energy from body stores (eg, adipose tissue), leading to reduced body weight. If the difference between energy intake and energy expenditure is positive, then energy is stored and body weight increases (a positive energy balance). Physiological processes strongly defend reductions in body weight arising from negative energy balance, ultimately leading to weight regain.⁴² In contrast, positive energy balance leads to weight gain and does not initiate the same physiological defense, leading to obesity. This new increased body weight is subsequently defended.⁴³ Energy balance becomes particularly important in periods of rapid growth, such as the adolescent growth spurt, with energy intake being one of the major determinants of growth.⁴⁴ However, the effect of energy intake on growth is predominantly indirect, with growth impairments due to undernutrition primarily attributable to endocrine changes such as increased circulating cortisol.^{45,46}

Energy homeostasis, and thus body weight, is both centrally and peripherally regulated through the processes of metabolism,^{40,47} as summarized in Table 1. When metabolic processes are functioning correctly, feedback mechanisms correct disruptions to energy homeostasis, with both the hypothalamus and brainstem sensing both short- and long-term changes in energy balance. At first, the response to a negative energy balance is the promotion of appetite/feeding behavior, the utilization of glycogen stores, and when these are exhausted, the utilization of adipose tissue stores, and finally the breakdown of lean muscle mass. However, as adolescent inhalant abuse is associated with both decreased food intake, impaired weight gain, and fasting hypoglycemia,^{26,27} this suggests that energy homeostasis is not being achieved and the feedback mechanisms, which should correct a negative energy balance, are dysfunctional.

5 | EFFECTS OF INHALANTS ON ENERGY BALANCE

Toluene has a complex pathway through the body. Once inhaled, toluene crosses rapidly from the lungs into the bloodstream via diffusion through the alveoli, before being metabolized by the liver and excreted by the kidneys.⁴⁸ The primary metabolic pathway of toluene is the formation of benzyl alcohol, with further oxidation to

| Key metabolic organ | Compound | Function |
|---------------------|----------------------------|---|
| Pancreas | Insulin | Decreases glucose levels in the blood by glycogenesis and promotes lipogenesis (the storage of energy as adipose tissue) |
| Pancreas | Amylin | Slows gastric emptying and reduces appetite |
| Pancreas | Glucagon | Promotes gluconeogenesis and the release of glycogen from stores if circulating glucose levels become too low |
| Liver | Insulin | Responds to insulin secreted by the pancreas by taking up glucose from the blood |
| Kidney | Insulin | Clears and degrades circulating insulin |
| Gut | Ghrelin | Increases hunger and initiates feeding |
| Gut | Mechanical processes | Stretch receptors signal satiety to the brain via the vagus nerve |
| Gut | Peptide YY (PYY) | Slows gastric emptying and reduces appetite |
| Adipose tissue | Leptin | Opposes the actions of ghrelin, by sending an adiposity signal and inhibiting hunger and also inhibits lipogenesis |
| Brain | Receptors for gut hormones | Signals converge primarily on the brain stem and hypothalamus, which are the primary brain regions involved in maintaining energy homeostasis |
| Brain | Neuropeptide Y (NPY) | Increases food intake |
| Adrenal gland | Adrenalin and cortisol | Responds to hypoglycemia by inhibiting insulin release, and activates glycogenolysis and gluconeogenesis, via the HPA axis |
| Bone | Osteocalcin | Increases insulin production and sensitivity, and enhances glucose utilization |

TABLE 1 Central and peripheral regulation of energy balance

benzaldehyde and benzoic acid, and then via conjugation to hippuric acid. Approximately 80% of absorbed toluene is excreted as hippuric acid in urine, with less than 1% excreted as o- and p-cresol, and up to 14% excreted by exhalation.⁴⁹⁻⁵¹ With repeated exposure, toluene can accumulate in organs, primarily the brain, adipose tissue, and adrenal glands,^{48,52} which are key regions for metabolic processes, compared to limited accumulation in liver, kidney, and muscle tissue.⁴⁸ Toluene can also cross⁵³ and disrupt⁵⁴ the blood-brain barrier and has a comparatively high accumulation in the brainstem and hypothalamus,⁵⁵ both areas playing a critical role in the control of feeding and metabolism.⁴⁷ This raises the potential that inhalant-induced metabolic dysfunction may have both centrally and peripherally mediated components.

The symptoms of inhalant abuse (ie, reduced food intake, body weight suppression, and impaired growth) are suggestive of a negative energy balance. However, questions remain as to which components of the energy balance equation are altered, and how the central and peripheral regulation of energy balance may be affected. Theoretically, inhalant abuse could reduce energy intake through a direct effect on appetite, or by increasing energy expenditure via changes to physical activity, basal metabolic rate, or thermogenesis. Inhalant abuse may also disrupt the metabolic signaling that would promote appetite and weight gain in response to a negative energy

balance. Alternatively, exposure to inhalants could also be directly affecting body composition through effects on the absorption or deposition of fat, or skeletal composition, which may explain growth impairments. Evidence suggests that inhalant abuse affects key metabolic organs (Figure 3), and each of these aspects of energy balance and energy balance regulation will be expanded upon in the following sections, as they are the key components to explore in order to understand the energy balance and growth effects of inhalant abuse.

6 | EFFECTS OF INHALANTS ON ENERGY INTAKE

In humans, there is evidence that incidental inhalation of petrol fumes may have an acute anorectic effect, and in a food-constrained environment, a desire to suppress feelings of hunger could be a driver for intentional petrol sniffing behavior.⁵⁶ These data support previous anecdotal reports that petrol sniffing in Australian Indigenous communities is partly driven by a desire to suppress appetite.²⁵ In adult rats, toluene-induced anorexia has been attributed in part to the observed decrease in the hypothalamic expression of neuropeptide Y (NPY), a peptide which stimulates food intake.³⁰ Furthermore, energy intake is moderated by absorption of nutrients occurring in the gut,




FIGURE 3 Key metabolic organs are affected by inhalant abuse, including the brain, pancreas, adipose tissue, bone, and adrenal glands

and disruptions to absorption are known to be associated with other types of substance abuse⁵⁷; however, we could find no studies that assessed nutrient absorption across the gut following toluene exposure or inhalant abuse. This is a potentially significant knowledge gap, given that inhalant users frequently report gastrointestinal disturbances, including nausea, vomiting, and diarrhea,^{18,58} and that gut microbiomes have never been assessed in relation to inhalant abuse.

Evidence also suggests that inhalant abuse can impair metabolic signaling, because the normal responses to negative energy balance are impaired. Food intake is reduced in rodents following exposure to toluene at abuse concentrations, with animals exposed to toluene consuming fewer kilocalories than air-exposed animals at the same body weight.²⁷ This suggests an impairment in metabolic feedback

processes, which should act to restore homeostasis in response to insufficient energy intake. In rats, adolescent toluene exposure alters the levels of gut hormones, including insulin, amylin, and peptide YY (PYY), and decreases hypothalamic leptin receptor mRNA expression.²⁷ Importantly, decreased amylin and PYY levels should act to increase appetite and food intake, but this does not occur, supporting the idea of impaired metabolic signaling. This hypothesized impairment is further supported by evidence that food intake recovers in abstinence; however, body weight suppression continues,²⁶ in contrast to the expected homeostatic recovery of body weight.⁴² These studies highlight that the observed growth changes, during both exposure and abstinence, are not directly correlated with food intake changes.




FIGURE 4 Inhalant abuse may alter both homeostatic and hedonic feeding pathways through multiple targets, including hypothalamic regulation of feeding and dopaminergic reward pathways. For simplicity, not all pathways, regions, or cell populations have been shown

7 | EFFECTS OF INHALANTS ON DIETARY PREFERENCES

In addition to changes in total energy intake, toluene has also been associated with alterations to dietary preferences and composition. Altered dietary intake alongside weight disruption has been reported in industrial workers chronically exposed to low toluene levels,⁵⁹ though this has not been explored in a clinical cohort of people who misuse inhalants. In these individuals, exposure to toluene results in an increase in the consumption of total calories and carbohydrates, even though body mass index remains the same. As toluene is also known to act on dopaminergic pathways,⁶⁰ it is possible that toluene may impact upon dopaminergic control of appetite and energy regulation (Figure 4). This may have long-term ramifications, as dopaminergic pathways have a well-established role in altering dietary preference⁶¹ including the potential to reinforce a high fat and high carbohydrate diet.⁶² Rats chronically exposed to high levels of toluene during adolescence exhibit a stronger preference for saccharin and for higher caloric chow compared to controls,⁶³ potentially through long-term consequences of toluene's effects on the mesocorticolimbic pathway (Figure 4). This may occur due to changes in hedonistic feeding pathways through alterations in reward signaling, or through the previously discussed homeostatic mechanisms to compensate for the body weight suppression that occurs during exposure. Altered glutamatergic signaling in the nucleus accumbens and dorsal striatum, through decreased NMDA receptor binding, was seen in a dose-dependent manner in rats chronically exposed to high levels of toluene during adolescence.²⁷ Toluene has also been shown to increase the level of dopamine in the nucleus accumbens in rats given a single dose,⁶⁴ and in the ventral tegmental area in vivo through direct actions on dopaminergic neurons in this area.⁶⁵

Future preclinical experiments using operant conditioning are required, both during active toluene exposure and abstinence, to systematically explore the effects of inhalants on dietary preferences and further characterize the role inhalants play in both hedonistic and homeostatic feeding, which could then be translated into clinical studies using nutritional assessment.

8 | EFFECTS OF INHALANTS ON GLYCEMIC CONTROL

High fat and high carbohydrate diets have been associated with changes in glycemic control, and increase the risk for development of type 2 diabetes.⁶⁶ This generally stems from ineffective insulin release and the development of insulin insensitivity, resulting in high, uncontrolled blood glucose levels that can have detrimental effects on the CNS, vision, and kidney function. Ultimately, if exposure to toluene alters glycemic control in association with a change in dietary preference, adolescent abusers could be predisposed to an increased risk of nutrition-related disorders later in life. The potential that toluene-induced metabolic dysfunction could increase the risk of diabetes is supported by studies of industrial workers exposed to

low levels of toluene. These individuals were found to have higher than normal insulin⁶⁷ and fasting blood glucose levels.^{67,68} This suggests that chronic toluene exposure may play a role in the development of insulin resistance and thus, altered glycemic control⁶⁸; the first step toward a diabetic phenotype, though the applicability in a clinical inhalant abuse context remains unknown.

In the clinical setting, a glucose tolerance test (GTT) is used to monitor how well glucose is metabolized and the capacity of the body to secrete adequate insulin. Typically, uncontrolled type 2 diabetic people have higher circulating glucose levels and a slower insulin response following a GTT. Adolescent rats chronically exposed to high doses of toluene demonstrated abnormal responses to GTT, including decreased insulin release.²⁷ Abnormal GTTs continued to be observed in these rats during abstinence following a period of access to a high fat and high carbohydrate diet, with significantly increased glucose levels compared to control rats on the same diet.²⁷ In contrast, however, adolescent rats chronically exposed to high concentrations of toluene exhibited low fasting blood glucose levels at the end of the exposure period, which could not be attributed solely to low food intake, as blood glucose levels were lower than pair-fed controls.²⁶ Additionally, these rats exhibited an increased glycemic response to an insulin tolerance test in comparison to controls, but an impaired glycemic response to a stress response test, with blood glucose disproportionately low compared to corticosterone response (which should promote an increase in blood glucose levels).²⁶

The mechanisms by which toluene impairs glycemic control are unknown. It is possible that toluene is directly disrupting the activity of glucose-sensing neuronal populations in the hypothalamus.⁶⁹ By interfering with the activity of these neurons, toluene-induced alterations to both feeding behavior and circulating hormone levels may occur. Hypothalamic damage has been reported in at least one patient chronically exposed to toluene during adolescence,⁷⁰ suggesting that toluene may exert effects directly within the CNS. This may cause downstream effects to peripheral systems involved in glycemic regulation impairing the ability to sense and respond to changing glucose levels. It is also possible that these results reflect differing effects over the time course of inhalant abuse; with low fasting blood glucose as a more immediate effect, but decreased insulin sensitivity developing over time, potentially in response to increased dietary preferences for carbohydrates.

9 | EFFECTS OF INHALANTS ON ENERGY EXPENDITURE

Energy expenditure in a clinical study of inhalant abuse has never been explicitly tested, but preclinical studies suggest that exposure to toluene affects components of energy expenditure. Toluene exposure in adolescents acutely increases locomotor activity,⁷¹ although this effect is transient and the response to toluene is biphasic with locomotor activity reduced at higher concentrations.⁷² In rats, adolescent exposure to toluene increased basal metabolism, particularly during the dark cycle.²⁶ In contrast, earlier studies had showed

that prenatal exposure to toluene resulted in reductions in metabolic rate and energy expenditure in the offspring, unfortunately this was not also assessed in the toluene-exposed individuals.²⁹ These studies also did not assess thermogenesis, in addition to physical activity or metabolic rate, but one study utilizing mice found that toluene acutely reduced core temperature in a dose-dependent manner.⁷³ Conversely, many inhalant users report a persistent low-grade fever,⁷⁴ although a mechanism for this remains unknown.

10 | EFFECTS OF INHALANTS ON ADIPOSE TISSUE

Adipose tissue is the major site of long-term energy storage in the body, and changes to adiposity will be reflected in changes to body weight. Therefore, adipose tissue is a key organ to consider in relation to adolescent inhalant abuse. Male adolescent rats exposed to toluene had significantly reduced adiposity but no difference in lean mass or total water²⁷ and a propensity for increased adipose tissue utilization over carbohydrate utilization.²⁶ Interestingly, in offspring that had prenatal exposure to toluene, body weight was also reduced, but toluene significantly increased adiposity in a dose-dependent way in male, but not female, offspring.²⁹ The increased adiposity was attributed to a compensatory developmental programming effect, whereby low birth weight alters hormonal and metabolic programming to maximize postnatal survival, and subsequently results in increased adiposity.⁷⁵ Furthermore, when there is a negative energy balance caused by insufficient food intake, adipose stores are utilized by the body to provide energy. Thus, the observed decrease in adiposity²⁷ associated with exposure to toluene may not be unexpected. However, alternative hypotheses as to why toluene reduces adiposity are that it affects the absorption of ingested fats within the digestive tract, or the ability to deposit lipids within adipose tissue, such as that observed in pancreatic disorders.⁷⁶ For example, both leptin and insulin play a crucial role in regulating lipogenesis⁷⁷ and, therefore, the observed disruptions to hormones involved in energy balance signaling, including insulin,²⁷ may impair the deposition of lipids in adipose tissue. While the studies discussed above show that exposure to toluene has an effect on body composition, particularly adiposity,²⁷ it has yet to be determined whether toluene has a direct effect on body composition, or if these changes are indirect effects arising as a result of decreased food intake leading to a negative energy balance.

11 | EFFECTS OF INHALANTS ON BONE

The reduction in weight gain arising from toluene exposure may not only be due to reduced adiposity, but also due to skeletal growth impairments. As well as a reduction in overall growth, inhalant abuse is associated with reduced bone density. A clinical study of adolescent males with a history of chronic glue sniffing found that bone mineral density was significantly reduced in comparison to an age-matched

nonsniffing group.⁷⁸ However, no other human studies on the effects of adolescent inhalant abuse on skeletal growth could be found. Male adolescent mice exposed to toluene have significantly reduced bone mineral density compared to controls,⁷⁹ although subsequent studies using rats did not find a reduction in bone density or skeletal microstructure following toluene exposure, rather that the bones were simply smaller.²⁶

It is possible that the metabolic perturbations observed in inhalant abuse could be involved in the reported skeletal growth impairments. Leptin has a direct effect on bone cell function and acts to reduce bone fragility through anabolic effects on osteoblasts and the reduction of osteoclast formation.⁸⁰ Amylin increases bone mass by inhibiting bone resorption.⁸¹ Insulin has an indirect effect on bone function, and increased circulating insulin is associated with increased bone density.⁸² All of these hormones are affected following exposure to toluene.^{27,67} A further consideration is that bone itself can also exert reciprocal effects upon metabolism via osteocalcin, which increases insulin production and sensitivity, and enhances glucose utilization.^{83,84} Osteocalcin can exert effects on both pancreatic β cells and adipocytes, making it a key component of metabolic regulation.⁸⁵ In combination, these developments led to the conclusion that there is reciprocal regulation between energy metabolism and bone metabolism.⁸⁶ Furthermore, this is mediated via the hypothalamus,⁸⁷ which is known to be affected by exposure to toluene.⁵⁵

12 | EFFECTS OF INHALANTS ON THE HYPOTHALAMIC-PITUITARY-ADRENAL (HPA) AXIS AND ADRENAL GLAND

There is evidence to suggest that inhalant abuse may affect the HPA axis, though the nature of this relationship is equivocal. Some studies have linked inhalant abuse with an upregulation in HPA axis activity and associated behaviors,⁸⁸⁻⁹⁰ whereas others have found a blunted HPA response following inhalant abuse.^{26,91,92} It is also possible that there is a direct effect of toluene on the adrenal gland, which is vulnerable to toxicological injury due to high vascularity and fat content,⁹³ particularly by aromatic hydrocarbons such as toluene.⁹⁴ Multiple preclinical studies have found that adrenal hypertrophy is evident following inhalant abuse,^{26,27,95,96} although only one clinical case study has associated inhalant abuse with an adrenal effect.⁹⁷

Adrenal hypertrophy can be an outcome of chronic stress or adrenal insufficiency.⁹⁸ Adrenal insufficiency is a failure to produce the stress hormone cortisol by the adrenal gland, either due to an issue in the adrenal gland (primary adrenal insufficiency) or impairment upstream in the HPA axis (secondary or tertiary adrenal insufficiency).⁹⁹ Chronic stress is characterized by adrenal hypertrophy with elevated levels of cortisol, whereas adrenal insufficiency is characterized by adrenal hypertrophy with low or unchanged levels of cortisol, which is then further located within the HPA axis by the relative levels of adrenocorticotropic hormone (ACTH) and corticotropin-releasing hormone (CRH).^{98,99}

When the adrenal gland has been directly investigated in relation to inhalant abuse, studies have found adrenal hypertrophy, particularly in the zona fasciculata where cortisol (corticosterone in rats) is produced, and low/unchanged levels of basal corticosterone with high levels of basal ACTH.^{26,95,96} Although these findings are diagnostically consistent with primary adrenal insufficiency,⁹⁹ in two earlier studies the authors attributed their findings to chronic stress,^{95,96} with a later study hypothesizing that adrenal insufficiency was present.²⁶ Adrenal insufficiency is a chronic disorder with symptoms of decreased food intake, impaired body weight and growth, nondiabetic fasting hypoglycemia, persistent low-grade fever, fatigue, and gastrointestinal disturbances.⁹⁹ These symptoms are consistent with what has been observed following inhalant abuse,^{20,24,26,27,58,74,100} although they also fit a range of other disorders. Nevertheless, there is potential that HPA axis dysfunction, particularly adrenal insufficiency, may underlie the growth and energy balance consequences of inhalant abuse.

13 | EFFECTS IN ABSTINENCE AND THE POTENTIAL FOR ADULT-ONSET DISORDERS

Some of the energy balance effects arising from adolescent inhalant abuse, including reduced body weight and linear growth, persist into abstinence.^{26,27,31} Severe and chronic weight suppression is associated with cognitive impairments¹⁰¹ and health effects, including kidney and bone damage.¹⁰² Additionally, growth impairments are associated with adverse psychological consequences, including social anxiety and poor self-image.^{103,104} Conversely, weight regain after a period of weight suppression is associated with increased central adiposity and insulin resistance, both of which are risk factors for the development of metabolic syndrome, obesity, and type 2 diabetes.^{42,105} Together this suggests that chronic toluene abuse could increase the risk of developing a diabetic phenotype, which is supported by human and rodent data linking impaired glucose tolerance to an increased risk of developing diabetes later in life. It is important to note, however, that it is currently equivocal whether weight suppression arising from adolescent inhalant abuse ultimately resolves, and this may be confounded in a clinical setting by other drug use during abstinence from inhalants.³¹ Nevertheless, adolescent inhalant abuse has the potential to initiate a sequence of long-term metabolic alterations and thus lead to a chronic disease burden for individuals, even if exposure ceases. However, the nature of that disease burden remains unknown and knowledge on the health consequences of inhalant abuse during abstinence is scarce.

14 | SUMMARY AND FUTURE WORK

The cognitive and neurological consequences of inhalant abuse have dominated inhalant abuse research. Long-term cognitive impairment arising from intentional inhalation of inhalants containing toluene is well reported,¹³⁻¹⁵ although in extended abstinence, these effects

generally improve and in some cases normalize completely.^{28,106,107} As discussed in this review, inhalant abuse is associated with decreased food intake, reduced body weight and linear growth, reduced adiposity, fasting hypoglycemia and altered glycemic regulation, altered levels of gut hormones, impaired HPA axis signaling as well as a preliminary link to impaired skeletal growth. These effects partially persist into sustained abstinence and cannot be solely attributed to reductions in food intake. Collectively, these symptoms suggest widespread energy balance dysfunction, which can impact growth and energy balance regulation, and may lead to an increased risk of chronic metabolic disorders for example, obesity and type 2 diabetes in adulthood, even if abuse ceases. However, the current state of research in this field does not enable determination of whether toluene predominantly affects the central or peripheral components of energy balance, nor enables us to determine the relative contributions of the effect on each organ, to the overall observed energy balance phenotype. Furthermore, the biochemical mechanisms underpinning these alterations have not yet been explored in detail.

These potential energy balance and growth impacts are not well-researched, and the lack of longitudinal cohorts of inhalant users means that the long-term health consequences of inhalant-induced energy balance dysfunction are unknown. Furthermore, while a dose-response relationship between toluene exposure and impaired body weight has been established, this has yet to be extended to other relevant endpoints, including changes to linear growth, dietary preferences, and metabolic signaling—such work would be highly valuable in distinguishing the impacts of occupational level exposure to toluene from inhalant abuse. Ultimately, we hope to stimulate additional research in this field, to further elucidate the long-term health risks associated with adolescent inhalant abuse and assist clinicians to treat individuals with a history of inhalant abuse, subsequently improving their quality of life.

ACKNOWLEDGEMENTS

This study was funded by the NHMRC, of which AJL is a Principal Research Fellow (1116930) and ZBA is a Senior Research Fellow (APP 1154974); RC was funded by an RTP Scholarship from the Australian Government. RC has received funding as an untied educational grant from Seqirus, unrelated to this study. We also acknowledge the Victorian Government's state infrastructure program.

ORCID

Rose Crossin  <https://orcid.org/0000-0003-1814-1330>

Ashleigh Qama  <https://orcid.org/0000-0001-8871-892X>

Zane B. Andrews  <https://orcid.org/0000-0002-9097-7944>

REFERENCES

1. Alcohol and other Drugs Council of Australia. *Policy Position - Inhalants*. Alcohol and other Drugs Council of Australia: Canberra; 2010.

2. Victorian Department of Human Services. *National Directions on Inhalant Abuse*. Victorian Department of Human Services: Melbourne; 2005.
3. United States National Library of Medicine. Household products database; 2019. Available from: <https://hpd.nlm.nih.gov/cgi-bin/household/search?tbl=TblChemicals&queryx=108-88-3> accessed 28 April 2019.
4. Villatoro JA, Cruz SL, Ortiz A, Medina-Mora ME. Volatile substance misuse in Mexico: correlates and trends. *Subst Use Misuse* 2011;46(sup1):40–45.
5. Bowen SE, Batis JC, Paez-Martinez N, Cruz SL. The last decade of solvent research in animal models of abuse: mechanistic and behavioral studies. *Neurotoxicol Teratol.* 2006;28:636–647.
6. Lubman D, Yücel M, Lawrence A. Inhalant abuse among adolescents: neurobiological considerations. *Br J Pharmacol.* 2008;154:316–326.
7. Andersen I, Lundqvist GR, Møhlave L, et al. Human response to controlled levels of toluene in six-hour exposures. *Scand J Work Environ Health.* 1983;154(2):316–326.
8. Dick RB, Setzer JV, Wait R, et al. Effects of acute exposure of toluene and methyl ethyl ketone on psychomotor performance. *Int Arch Occup Environ Health.* 1984;54:91–109.
9. White V, Williams T. *Australian Secondary School Students' Use of Tobacco, Alcohol, and Over-the-Counter and Illicit Substances in 2014*. Australia, Cancer Council Victoria for Australian Government Department of Health: Melbourne; 2016.
10. Australian Institute of Health and Welfare. *National Drug Strategy Household Survey 2016*. Australian Institute of Health and Welfare: Canberra; 2016.
11. Dell CA, Gust SW, MacLean S. Global issues in volatile substance misuse. *Subst Use Misuse.* 2011;46(sup1):1–7.
12. Johnston LD, Miech RA, O'Malley PM, Bachman JG, Schulenberg JE, Patrick ME. *Monitoring the Future - Key Findings on Adolescent Drug Use 2017 overview*. Ann Arbor: The University of Michigan; 2017.
13. Hormes JT, Filley CM, Rosenberg NL. Neurologic sequelae of chronic solvent vapor abuse. *Neurology.* 1986;36:698–698.
14. Knox JW, Nelson JR. Permanent encephalopathy from toluene inhalation. *N Engl J Med.* 1966;275:1494–1496.
15. Maruff P, Burns C, Tyler P, Currie B, Currie J. Neurological and cognitive abnormalities associated with chronic petrol sniffing. *Brain.* 1998;121:1903–1917.
16. Cruz SL, Torres-Flores M, Galván EJ. Repeated toluene exposure alters the synaptic transmission of layer 5 medial prefrontal cortex. *Neurotoxicol Teratol.* 2019;73:9–14.
17. Furlong TM, Duncan JR, Corbit LH, et al. Toluene inhalation in adolescent rats reduces flexible behaviour in adulthood and alters glutamatergic and GABAergic signalling. *J Neurochem.* 2016;139:806–822.
18. Kurtzman TL, Otsuka KN, Wahl RA. Inhalant abuse by adolescents. *J Adolesc Health.* 2001;28:170–180.
19. Crossin R, Cairney S, Lawrence AJ, Duncan JR. Adolescent inhalant abuse leads to other drug use and impaired growth; implications for diagnosis. *Aust N Z J Public Health.* 2017;41:99–104.
20. Glaser HH, Massengale ON. Glue-sniffing in children: Deliberate inhalation of vaporized plastic cements. *J Am Med Assoc.* 1962;181:300–303.
21. Ryu YH, Lee JD, Yoon PH, Jeon P, Kim DI, Shin DW. Cerebral perfusion impairment in a patient with toluene abuse. *J Nucl Med.* 1998;39:632–633.
22. Crossin R, Lawrence A, Andrews Z, Churilov L, Duncan J. Growth changes after inhalant abuse and toluene exposure: a systematic review and meta-analysis of human and animal studies. *Hum Exp Toxicol.* 2018;39(4):632–633
23. Alcohol and Drug Foundation. Drug facts: inhalants. 2015. Retrieved 20/05/2018, 2018, from <http://www.druginfo.adf.org.au/drug-facts/inhalants>.
24. Pisetsky EM, May Chao Y, Dierker LC, May AM, Striegel-Moore RH. Disordered eating and substance use in high-school students: results from the youth risk behavior surveillance system. *Int J Eat Disord.* 2008;41:464–470.
25. Brady M. *Heavy Metal: The Social Meaning of Petrol Sniffing in Australia*. Canberra: Aboriginal Studies Press; 1992.
26. Crossin R, Andrews ZB, Sims NA, et al. Adolescent inhalant abuse results in adrenal dysfunction and a hypermetabolic phenotype with persistent growth impairments. *Neuroendocrinology.* 2018;107:340–354.
27. Dick A, Pooters T, Gibbs S, et al. NMDA receptor binding is reduced within mesocorticolimbic regions following chronic inhalation of toluene in adolescent rats. *Brain Res.* 2015;1624:239–252.
28. Duncan JR, Dick A, Egan G, et al. Adolescent toluene inhalation in rats affects white matter maturation with the potential for recovery following abstinence. *PLoS ONE.* 2012;7:e44790.
29. Jarosz PA, Fata E, Bowen SE, Jen K, Coscina DV. Effects of abuse pattern of gestational toluene exposure on metabolism, feeding and body composition. *Physiol Behav.* 2008;93:984–993.
30. Morón L, Pascual J, Portillo P, et al. Toluene alters appetite, NPY, and galanin immunostaining in the rat hypothalamus. *Neurotoxicol Teratol.* 2004;26:195–200.
31. Crossin R, Cairney S, John Lawrence A, Rubina Duncan J. The persistence of growth impairments associated with adolescent inhalant abuse following sustained abstinence. *Addict Res Theory.* 2018;26:183–186.
32. Pryor GT. A toluene-induced motor syndrome in rats resembling that seen in some human solvent abusers. *Neurotoxicol Teratol.* 1991;13:387–400.
33. Tanner J, Whitehouse R. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. *Arch Dis Child.* 1976;51:170–179.
34. Bonjour J-P, Theinitz G, Buchs B, Slosman D, Rizzoli R. Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence*. *J Clin Endocrinol Metab.* 1991;73:555–563.
35. Gordon C. Measurement of bone density in children. *Curr Opin Endocr Metab Res.* 2005;12:444–451.
36. Dreizen S, Spirakis CN, Stone RE. A comparison of skeletal growth and maturation in undernourished and well-nourished girls before and after menarche. *J Pediatr.* 1967;70:256–263.
37. Golub MS, Hogrefe CE, Germann SL, Lasley BL, Natarajan K, Tarantal AF. Effects of exogenous estrogenic agents on pubertal growth and reproductive system maturation in female rhesus monkeys. *Toxicol Sci.* 2003;74:103–113.
38. Martorell R, Khan LK, Schroeder DG. Reversibility of stunting: epidemiological findings in children from developing countries. *Eur J Clin Nutr.* 1994;48:S45–57.
39. Reed RB, Stuart HC. Patterns of growth in height and weight from birth to eighteen years of age. *Pediatrics.* 1959;24:904–921.
40. Woods SC, Seeley RJ, Porte D, Schwartz MW. Signals that regulate food intake and energy homeostasis. *Science.* 1998;280:1378–1383.
41. Keesey RE, Powley TL. Body energy homeostasis. *Appetite.* 2008;51:442–445.
42. Sumithran P, Proietto J. The defence of body weight: a physiological basis for weight regain after weight loss. *Clin Sci.* 2013;124:231–241.
43. Keesey RE. Physiological regulation of body weight and the issue of obesity. *Med Clin North Am.* 1989;73:15–27.
44. Rogol AD, Clark PA, Roemmich JN. Growth and pubertal development in children and adolescents: effects of diet and physical activity. *Am J Clin Nutr.* 2000;72:S21S–S28S.
45. Miller KK. Endocrine effects of anorexia nervosa. *Endocrinol Metab Clin North Am.* 2013;42:515.
46. Munoz M, Argente J. Anorexia nervosa in female adolescents: endocrine and bone mineral density disturbances. *Eur J Endocrinol.* 2002;147:275–286.

47. Schwartz MW, Woods SC, Porte D, Seeley RJ, Baskin DG. Central nervous system control of food intake. *Nature*. 2000;404:661-671.
48. Sato A, Nakajima T, Fujiwara Y, Hirose K. Pharmacokinetics of benzene and toluene. *Int Arch Arbeitsmed*. 1974;33:169-182.
49. Andersson R, Carlsson A, Nordqvist MB, Sollenberg J. Urinary excretion of hippuric acid and o-cresol after laboratory exposure of humans to toluene. *Int Arch Occup Environ Health*. 1983;53:101-108.
50. Carlsson A. Exposure to toluene: uptake, distribution and elimination in man. *Scand J Work Environ Health*. 1982;43-55.
51. Löf A, Hjelm EW, Colmsjö A, Lundmark BO, Norström A, Sato A. Toxicokinetics of toluene and urinary excretion of hippuric acid after human exposure to 2H8-toluene. *Occup Environ Med*. 1993;50:55-59.
52. Pyykkö K, Tähti H, Vapaatalo H. Toluene concentrations in various tissues of rats after inhalation and oral administration. *Arch Toxicol*. 1977;38:169-176.
53. Gerasimov M, Ferrieri R, Schiffer W, et al. Study of brain uptake and biodistribution of [¹¹C] toluene in non-human primates and mice. *Life Sci*. 2002;70:2811-2828.
54. Mathew RJ, Wilson WH. Substance abuse and cerebral blood flow. *Am J Psychiatry*. 1991;148:292.
55. Ameno K, Kiri T, Fuke C, Ameno S, Shinohara T, Ijiri I. Regional brain distribution of toluene in rats and in a human autopsy. *Archiv Toxicol*. 1992;66:153-156.
56. Jackson CE, Currie BJ, Cairney S, Maruff PT, Snyder PJ. Hunger and the perception of the scent of petrol: A potential neurobiological basis for increased risk of petrol inhalation abuse. *Addict Res Theory*. 2009;17:518-524.
57. Bode C, Bode JC. Effect of alcohol consumption on the gut. *Best Pract Res Clin Gastroenterol*. 2003;17:575-592.
58. Anderson CE, Loomis GA. Recognition and prevention of inhalant abuse. *Am Family Phys*. 2003;68:869-874.
59. Wang D-H, Ishii K, Seno E, et al. Reduced serum levels of ALT and GGT and high carbohydrate intake among workers exposed to toluene below the threshold limit values. *Ind Health*. 1998;36:14-19.
60. Riegel AC, French ED. Abused inhalants and central reward pathways: electrophysiological and behavioral studies in the rat. *Ann NY Acad Sci*. 2002;965:281-291.
61. Hardman CA, Herbert VM, Brunstrom JM, Munafò MR, Rogers PJ. Dopamine and food reward: effects of acute tyrosine/phenylalanine depletion on appetite. *Physiol Behav*. 2012;105:1202-1207.
62. Zheng H, Berthoud H-R. Eating for pleasure or calories. *Curr Opin Pharmacol*. 2007;7:607-612.
63. Dick AL, Simpson A, Qama A, Andrews Z, Lawrence AJ, Duncan JR. Chronic intermittent toluene inhalation in adolescent rats results in metabolic dysfunction with altered glucose homeostasis. *Br J Pharmacol*. 2015;172:5174-5187.
64. Riegel A, Ali S, French E. Toluene-induced locomotor activity is blocked by 6-hydroxydopamine lesions of the nucleus accumbens and the mGluR2/3 agonist LY379268. *Neuropsychopharmacology*. 2003;28:1440-1447.
65. Riegel A, Zapata A, Shippenberg T, French E. The abused inhalant toluene increases dopamine release in the nucleus accumbens by directly stimulating ventral tegmental area neurons. *Neuropsychopharmacology*. 2007;32:1558-1569.
66. van Dam RM, Rimm EB, Willett WC, Stampfer MJ, Hu FB. Dietary patterns and risk for type 2 diabetes mellitus in US men. *Ann Intern Med*. 2002;136:201-209.
67. Won YL, Ko Y, Heo K-H, Ko KS, Lee M-Y, Kim K-W. The effects of long-term, low-level exposure to monocyclic aromatic hydrocarbons on worker's insulin resistance. *Saf Health Work*. 2011;2:365-374.
68. Kaukiainen A, Vehmas T, Rantala K, Nurminen M, Martikainen R, Taskinen H. Results of common laboratory tests in solvent-exposed workers. *Int Arch Occup Environ Health*. 2004;77:39-46.
69. Levin BE, Dunn-Meynell AA, Routh VH. Brain glucose sensing and body energy homeostasis: role in obesity and diabetes. *Am J Physiol-Regul Integr Comp Physiol*. 1999;276:R1223-R1231.
70. Teelucksingh S, Steer C, Thompson C, Douglas N, Edwards C. Hypothalamic syndrome and central sleep apnoea associated with toluene exposure. *QJM*. 1991;78:185-190.
71. Bowen SE, Charlesworth JD, Tokarz ME, Wright MJ, Wiley JL. Decreased sensitivity in adolescent vs. adult rats to the locomotor activating effects of toluene. *Neurotoxicol Teratol*. 2007;29:599-606.
72. Batis JC, Hannigan JH, Bowen SE. Differential effects of inhaled toluene on locomotor activity in adolescent and adult rats. *Pharmacol Biochem Behav*. 2010;96:438-448.
73. Paez-Martinez N, Aldrete-Audiffred J, Gallardo-Tenorio A, Castro-García M, Estrada-Camarena E, Lopez-Rubalcava C. Participation of GABA_A, GABA_B receptors and neurosteroids in toluene-induced hypothermia: evidence of concentration-dependent differences in the mechanism of action. *Eur J Pharmacol*. 2013;698:178-185.
74. Connors NJ. Inhalants clinical presentation. 2017. Retrieved 20 March 2018, 2018, from <https://emedicine.medscape.com/article/1174630-clinical>.
75. Hales CN, Barker DJ. The thrifty phenotype hypothesis. *Br Med Bull*. 2001;60:5-20.
76. DiMagno EP, Go VL, Summerskill W. Relations between pancreatic enzyme outputs and malabsorption in severe pancreatic insufficiency. *N Engl J Med*. 1973;288:813-815.
77. Kersten S. Mechanisms of nutritional and hormonal regulation of lipogenesis. *EMBO Rep*. 2001;2:282-286.
78. Dündaröz MR, Sarici S, Turkbay T. Evaluation of bone mineral density in chronic glue sniffers. *Turk J Pediatr*. 2002;44:326-329.
79. Atay AA, Kismet E, Turkbay T, et al. Bone mass toxicity associated with inhalation exposure to toluene. *Biol Trace Elem Res*. 2005;105:197-203.
80. Cornish J, Callon K, Bava U, et al. Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. *J Endocrinol*. 2002;175:405-415.
81. Cornish J, Callon KE, King AR, Cooper GJ, Reid IR. Systemic administration of amylin increases bone mass, linear growth, and adiposity in adult male mice. *Am J Physiol-Endocrinol Metab*. 1998;275:E694-E699.
82. Haffner SM, Bauer RL. The association of obesity and glucose and insulin concentrations with bone density in premenopausal and postmenopausal women. *Metabolism*. 1993;42:735-738.
83. Hwang Y-C, Jeong I-K, Ahn K-J, Chung H-Y. Circulating osteocalcin level is associated with improved glucose tolerance, insulin secretion and sensitivity independent of the plasma adiponectin level. *Osteoporos Int*. 2012;23:1337-1342.
84. Lee NK, Sowa H, Hinoi E, et al. Endocrine regulation of energy metabolism by the skeleton. *Cell*. 2007;130:456-469.
85. Ferron M, Hinoi E, Karsenty G, Ducy P. Osteocalcin differentially regulates β cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. *Proc Natl Acad Sci*. 2008;105:5266-5270.
86. Lee NK, Karsenty G. Reciprocal regulation of bone and energy metabolism. *Trends Endocrinol Metab*. 2008;19:161-166.
87. Karsenty G. Convergence between bone and energy homeostases: leptin regulation of bone mass. *Cell Metab*. 2006;4:341-348.
88. Bowen SE, Hannigan JH, Davidson CJ, Callan SP. Abstinence following toluene exposure increases anxiety-like behavior in mice. *Neurotoxicol Teratol*. 2017.
89. Hsieh G, Sharma R, Parker R. Hypothalamic-pituitary-adrenocortical axis activity and immune function after oral exposure to benzene and toluene. *Immunopharmacology*. 1991;21:23-32.
90. Paez-Martinez N, Flores-Serrano Z, Ortiz-Lopez L, Ramirez-Rodriguez G. Environmental enrichment increases

- doublecortin-associated new neurons and decreases neuronal death without modifying anxiety-like behavior in mice chronically exposed to toluene. *Behav Brain Res.* 2013;256:432-440.
91. Bowen SE, Wiley JL, Balster RL. The effects of abused inhalants on mouse behavior in an elevated plus-maze. *Eur J Pharmacol.* 1996;312:131-136.
 92. Hougaard KS, Hansen ÅM, Hass U, Lund SP. Toluene depresses plasma corticosterone in pregnant rats. *Basic Clin Pharmacol Toxicol.* 2003;92:148-152.
 93. Harvey PW, Everett DJ, Springall CJ. Adrenal toxicology: a strategy for assessment of functional toxicity to the adrenal cortex and steroidogenesis. *J Appl Toxicol.* 2007;27:103-115.
 94. Verma Y, Rana S. Endocrinal toxicity of industrial solvents—a mini review. *Indian J Exp Biol.* 2009;47:537-549.
 95. Gotohda T, Tokunaga I, Kubo S-I. Toluene inhalation-induced adrenocortical hypertrophy and endocrinological changes in rat. *Life Sci.* 2005;76:1929-1937.
 96. Yang M, Kim S-H, Kim J-C, Shin T, Moon C. Toluene induces depression-like behaviors in adult mice. *Toxicol Res.* 2010;26:315.
 97. Kamijo Y, Soma K, Hasegawa I, Ohwada T. Fatal bilateral adrenal hemorrhage following acute toluene poisoning: a case report. *J Toxicol Clin Toxicol.* 1998;36:365-368.
 98. Harvey PW, Sutcliffe C. Adrenocortical hypertrophy: establishing cause and toxicological significance. *J Appl Toxicol.* 2010;30:617-626.
 99. Arlt W, Allolio B. Adrenal insufficiency. *Lancet.* 2003;361:1881-1893.
 100. Canadian Paediatric Society, F. N., Inuit and M. H. C. B. L. Inhalant abuse. *Paediatr Child Health.* 2010;15:443-448.
 101. Kretsch M, Green M, Fong A, Elliman N, Johnson H. Cognitive effects of a long-term weight reducing diet. *Int J Obes.* 1997;21:14-21.
 102. Sharp C, Freeman C. The medical complications of anorexia nervosa. *Br J Psychiatry.* 1993;162:452-462.
 103. Molinari E, Sartorio A, Ceccarelli A, Marchi S. Psychological and emotional development, intellectual capabilities, and body image in short normal children. *J Endocrinol Invest.* 2002;25:321-328.
 104. Siegel P, Clopper R, Stabler B. Psychological impact of significantly short stature. *Acta Paediatr Scand.* 1991;108(6):1107-1114.
 105. Dulloo AG, Jacquet J, Seydoux J, Montani J-P. The thrifty 'catch-up fat' phenotype: its impact on insulin sensitivity during growth trajectories to obesity and metabolic syndrome. *Int J Obes.* 2006;30:S23-S35.
 106. Cairney S, Maruff P, Burns CB, Currie J, Currie BJ. Neurological and cognitive recovery following abstinence from petrol sniffing. *Neuropsychopharmacology.* 2005;30:1019-1027.
 107. Cairney S, O'Connor N, Dingwall KM, et al. A prospective study of neurocognitive changes 15 years after chronic inhalant abuse. *Addiction.* 2013;108:1107-1114.
 108. Crossin R, Lawrence AJ, Andrews ZB, Duncan JR. Altered body weight associated with substance abuse: a look beyond food intake. *Addict Res Theory.* 2018;30(5):1019-1027.

How to cite this article: Crossin R, Qama A, Andrews ZB, Lawrence AJ, Duncan JR. The effect of adolescent inhalant abuse on energy balance and growth. *Pharmacol Res Perspect.* 2019;e00498. <https://doi.org/10.1002/prp2.498>